Amgen deal, $60M venture round allow Volastra Therapeutics to advance pair of KIF18A products. BioCentury's BioCentury speaks to the NYC biotech on how the deal came together, and what's next $AMGN $LLY $BMY buff.ly/3YtF7OM

Well, what a week it's been huh $SIVB

You know where the biotech sector is when RIF becomes the three letter word more frequently used than IPO.

$BCYC and Bayer Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology. Bicycle Therapeutics to receive upfront payment of $45M

Close to $ 100m in non-dilutive cash for platform access for Bicycle this year. Novartis & Bayer are the 2 parties really putting effort in radiopharmaceuticals, now both entangled with $BCYC

#ASCO23 Bicara's impressive data in head and neck cancer (48% ORR, 65% in HPV negative disease) potential beats Keytruda, and has the private group making pivotal plans. I spoke to CEO Claire Mazumdar: evaluate.com/vantage/articl… $MRK

Anyone on biotwitter with an informed opinion on $ZLAB and its current valuation? Curious on how to make the numbers work here. Simply a bad case of China/governmental-overhang?

With everyone staring their eyes out at $MLTX, it's surprising how little attention $UCB's bimekizumab generates. Massively overlooked mid size pharma cursed with pipeline assets with great MoAs but high-profile peers: IL17A/F, FcRn

The Baker Bros / Seagen story remains mesmerizing to me. $SGEN represents 47% of the BB portfolio, as these guys get ready for a $10bn pay day from Pfizer's acquisition. How do you redeploy $ 10bn within biotech?!

Daiichi follows up with another monster ADC deal, now with Merck after doing the first batch with AstraZeneca. Pressure of next gen ADC tech has increased though.

Another great ADC in ovarian cancer, another great ADC by Daiichi. Tough tox profile, likely driven by high dose 8mg/kg excluded for further exploration #ESMO23

Breaking #News: Genmab to broaden and strengthen its #oncology portfolio with the proposed acquisition of ProfoundBio, a biotechnology company focused on the development of novel #AntibodyDrugConjugate therapies. Learn more at: gmab.ly/HIsX50R7akt

$GMAB swinging for the fences this morning. Great to see European big biotech dip its toes in meaningful M&A. $ 1.8bn sure is a significant ticket for a phase I/II FRa ADC, one of the most crowded targets around.

While many people focus on the set of FRa ADCs with today's acquisition of ProfoundBio by $GMAB, I would argue raludotatug deruxtecan is another formidable competitor in the ovarian cancer field.

Presumably this is a mechanistic manifestation of long-term exposure, so 601 (next-gen Vox) likely done too Probably a win for orthogonal / polymerization-independent MOAs like $AGIO and $FULC, but will patients actually take them?

$LBPH fun fact on Longboard M&A: Lundbeck CEO Charl van Zyl was previously EVP neurology at UCB when they bought Zogenix for Fintepla, the very molecule bexicaserin is trying to improve on.

Did the market expect $DYN to radically outperform $RNA? DM1 drug candidates look pretty similar and suddenly Dyne is heading into registrational cohort with 32 pts on 6M endpoint vs Avidity's 150 ph3 trial on 30w endpt. Time to market looks very close.

Is this $ARGX starting to be valued as a pharma company rather than a development biotech? Are investors now looking at EPS & PE multiples rather than pipeline promise? In any case, it's a momentous occasion to see them transition into profitability, what a behemoth of a company

LIFE’S CERTAINTIES: Roses are red Eric Tokat has a mission Centerview partners Acted as financial advisor to this acquisition

The insistence on absurd and public flattery for the leader is a hallmark of authoritarianism. This kind of enforced sycophancy is not just ridiculous - it is dangerous. ft.com/content/4052d8… via @ft